The newest fast weight loss pill is now on the market.

By John D Greene


One of the most serious health threats facing Americans today is the malady designated as obesity. There are 500 million Adults, a whopping 31 percent of the population, who are not simply overweight; they are classified as unable to enjoy optimum health and activity because of their weight.

The health risks most commonly linked to obesity are heart attack, stroke, high blood pressure, high cholesterol, and diabetes. The annual medical costs associated with these ills are astronomical. The risk of health issues are high for those who are overweight, however, when one is obese, the chance of risk rises exponentially.

On the new product front, there is great news. Vivus Pharmaceuticals have recently announced a new weight loss pill, designated for considerable weight loss for obese patients. This groundbreaking medication is named Qsymia, a weight loss pill that was recently approved for prescription by the Food and drug administration.

Approval for weight loss drugs is significant in light of the fact that the FDA has not approved any drugs for weight loss in the past 10 years. Thus the weight loss pill passed FDA approval under considerable scrutiny. Qsymia is a combination drug, two drugs working together as one. Both of these drugs have enjoyed various rates of success in weight loss therapy. It was the innovative approach of Vivus to put them together.

This weight loss drug among other things, is approved under strenuous clinical study. Patients were monitored while on Qsymia for 12 consecutive months. In one study, patients lost an average of 6.7 per cent of body weight, while in the other, patients lost an average of 8.9 per cent. Patients on the highest dosages reported significant body weight loss as high as 22 pounds.

Researchers have determined that Qsymia is so effective because it targets two completely separate areas that cause overeating. The drugs that comprise the weight loss pill are Topiramate and Phentermine. The former is an anti-consultant, which makes the patient feel more satisfied after a meal. The latter is an appetite suppressant.

Research also has shown that the continued weight loss helps control other health conditions. Patients and their physicians report over extended use, that blood pressure decreases, and diabetic therapy is significantly reduced. It is also reported that symptoms associated with sleep apnea are lessened.

Qsymia has been approved for use, but not unrestricted use. Current guidelines suggest that the drug only be prescribed for patient with a BMI (Body mass index) greater than 30. In other words, the drug is for those clinically revealed as obese. In addition, Physicians and clinics that administer the drug are advised to closely monitor the patients. Side effects include congenital disorder in infants, if taken by women who are pregnant.

Physicians and clinics on the leading edge of practice have adapted their offerings to their patients based on the results of these studies. They see this as another tool to wage battle against obesity. One such company; Equilibrium Weight loss and Longevity offers Qsymia as part of a comprehensive line of weight loss protocols.




About the Author:



No comments:

Post a Comment